Fig. 2
From: Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
A Cumulative incidence of major cardiovascular events (MACE) across time following acalabrutinib initiation. B. Risk of developing MACE defined by hazard ratio (HR) stratified by peak systolic blood pressure (SBP) increase within 1 year of acalabrutinib initiation. Dotted line represents hazard ratio = 1. *Asterisks denote statistical tests that did not converge or strata with ≤ 3 patients